Home / Business and Economy / Lilly's $1.4T Bet: Weight Loss Drug's Double-Edged Sword

Lilly's $1.4T Bet: Weight Loss Drug's Double-Edged Sword

Summary

  • Experimental drug causes extreme weight loss, alarming some participants.
  • Eli Lilly faces patent expirations and competitor drug advancements.
  • Investor optimism for Eli Lilly's pipeline may overlook significant risks.

In December 2025, Eli Lilly CEO David Ricks encountered an unusual challenge: his experimental weight loss drug, retatrutide, was proving too effective. Participants in the highest dosage group lost an average of 28.7% of their body weight over 68 weeks, with some discontinuing treatment due to significant side effects or perceived excessive weight loss.

Lilly currently leads the GLP-1 market, surpassing Novo Nordisk with combined sales of $36 billion from Mounjaro and Zepbound last year. Analysts project these sales to exceed $88 billion by 2030, driven by drug potency and Lilly's consumer-centric market strategy.

However, Lilly's considerable $1.4 trillion valuation may not fully account for looming threats. Semaglutide, the active ingredient in Novo Nordisk's key drugs, faces patent expiration in 2031, opening the door for generic versions that could significantly reduce prices across the category.

Additionally, the emergence of oral weight-loss alternatives and the potential for competitors to develop better-tolerated drugs present further challenges. Investors are betting heavily on Lilly's pipeline, with analysts estimating the net present value of its current and experimental drugs at approximately $647 billion.

This valuation implies that a substantial portion of Lilly's market value relies on investor confidence in experimental therapies and stronger-than-forecasted sales. The company's upcoming "Innovation Day" on December 7 in Boston could reveal more about its future strategy, including potential monthly retatrutide formulations.

Despite the excitement surrounding Lilly's pipeline, the company trades at a high valuation compared to competitors and the industry average. This leaves little room for error, especially considering the high failure rate for drugs in development, where 90% never reach the market.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571